Modified/chimeric superantigens and their use
CA 2222757 C · Owner: Kalland, Terje · Inventors: Kalland, Terje; Bjork, Per; Dohlsten, Mikael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A conjugate between a target-seeking moiety and a modified superantigen characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV.beta. and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In a preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I SA II etc.) , characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 26, 1997 and granted July 26, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 26, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 26, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.